Document:

EX-4.1

 Exhibit 4.1 

FIRST SUPPLEMENTAL INDENTURE 

This First Supplemental Indenture (this “Supplemental Indenture”), dated as of January 5, 2022, among Federal
Realty OP LP, a Delaware limited partnership (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”). 

BACKGROUND 
 A. The Company,
formerly known as Federal Realty Investment Trust, a Maryland real estate investment trust, has undertaken a reorganization (the “Reorganization”) pursuant to which: 

 

	 	(1)	 The Company formed a wholly-owned subsidiary Maryland real estate investment trust
(“Holdco”). 

  

	 	(2)	 Holdco formed a wholly-owned subsidiary Maryland real estate investment trust (“Merger
Sub”). 

  

	 	(3)	 Effective as of 12:00 a.m. on January 1, 2022, Merger Sub merged with and into the Company, with the
Company being the surviving entity (the “Merger”), and the Company changed its name to Federal Realty Interim Real Estate Investment Trust. 

 

	 	(4)	 Following the Merger, Holdco changed its name to “Federal Realty Investment Trust” (the former name
of the Company), and the Company converted to a Delaware limited partnership named “Federal Realty OP LP” (the “Conversion”). 

 

	 	(5)	 Holdco will be the sole initial limited partner of the Company following the Conversion. Federal Realty GP LLC,
a Delaware limited liability company and wholly-owned subsidiary of Holdco, will be the initial general partner of the Company. 

B. The Company and the Trustee are parties to that certain Indenture dated as of December 1, 1993 (the
“Indenture”). 
 C. The Reorganization is permitted by the Indenture, including Section 801 thereof, without the
consent of the Holders, and the Company will deliver to the Trustee an Officers’ Certificate and Opinion of Counsel to that effect. 

D. In connection with the Reorganization, the Company and the Trustee desire to enter into this Supplemental Indenture pursuant to
Section 901(9) of the Indenture, which provides that, without the consent of any Holders of Securities or coupons, the Company, when authorized by or pursuant to a Board Resolution, and the Trustee, at any time and from time to time, may enter
into one or more indentures supplemental to the Indenture, in form satisfactory to the Trustee, to cure any ambiguity or to correct defective provisions therein. 

 AGREEMENT 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Trustee
hereby agree as follows: 
 1. Usage of Terms. Effective immediately following the effectiveness of the Conversion, on the date of
this Supplemental Indenture, to cure an ambiguity resulting therefrom: 
  

	 	a.	 The definition of the term “Board of Trustees” in Section 101 of the Indenture shall be amended
in its entirety to read as follows: “Board of Trustees” means the board of trustees of Federal Realty Investment Trust, a Maryland real estate investment trust, the executive committee thereof or any committee of that board duly
authorized hereunder. 

  

	 	b.	 As used in (i) the defined terms “Company Request,” “Company Order” and
“Officers’ Certificate” and (ii) Section 303 of the Indenture, the term “trustee” shall be understood to mean a member of the Board of Trustees of Federal Realty Investment Trust, a Maryland real estate investment
trust. 

 2. Capitalized Terms. Capitalized terms used but not defined herein shall have the meanings given to them
in the Indenture. 
 3. Governing Law. This Supplemental Indenture shall be governed by and construed in accordance with the law of
the State of New York. 
 4. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy
shall be an original, but all of them together represent the same agreement. 
 5. The Trustee. The Trustee shall not be responsible
in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company. 

[Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

			
	FEDERAL REALTY OP LP
		
	By:	 	 /s/ Dawn M. Becker

		 	Name: Dawn M. Becker
		 	Title:   Executive Vice President-Corporate
	
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/ Paul Vaden

		 	Name: Paul Vaden
		 	Title:   Vice President

  

  
 First Supplemental
Indenture – 1993 IndentureEX-4.2

 Exhibit 4.2 

FIRST SUPPLEMENTAL INDENTURE 

This First Supplemental Indenture (this “Supplemental Indenture”), dated as of January 5, 2022, among Federal
Realty OP LP, a Delaware limited partnership (the “Company”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”). 

BACKGROUND 
 A. The Company,
formerly known as Federal Realty Investment Trust, a Maryland real estate investment trust, has undertaken a reorganization (the “Reorganization”) pursuant to which: 

 

	 	(1)	 The Company formed a wholly-owned subsidiary Maryland real estate investment trust
(“Holdco”). 

  

	 	(2)	 Holdco formed a wholly-owned subsidiary Maryland real estate investment trust (“Merger
Sub”). 

  

	 	(3)	 Effective as of 12:00 a.m. on January 1, 2022, Merger Sub merged with and into the Company, with the
Company being the surviving entity (the “Merger”), and the Company changed its name to Federal Realty Interim Real Estate Investment Trust. 

 

	 	(4)	 Following the Merger, Holdco changed its name to “Federal Realty Investment Trust” (the former name
of the Company), and the Company converted to a Delaware limited partnership named “Federal Realty OP LP” (the “Conversion”). 

 

	 	(5)	 Holdco will be the sole initial limited partner of the Company following the Conversion. Federal Realty GP LLC,
a Delaware limited liability company and wholly-owned subsidiary of Holdco, will be the initial general partner of the Company. 

B. The Company and the Trustee are parties to that certain Indenture dated as of September 1, 1998 (the
“Indenture”). 
 C. The Reorganization is permitted by the Indenture, including Section 801 thereof, without the
consent of the Holders, and the Company will deliver to the Trustee an Officers’ Certificate and Opinion of Counsel to that effect. 

D. In connection with the Reorganization, the Company and the Trustee desire to enter into this Supplemental Indenture pursuant to
Section 901(9) of the Indenture, which provides that, without the consent of any Holders of Securities or coupons, the Company, when authorized by or pursuant to a Board Resolution, and the Trustee, at any time and from time to time, may enter
into one or more indentures supplemental to the Indenture, in form satisfactory to the Trustee, to cure any ambiguity or to correct defective provisions therein. 

AGREEMENT 
 NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Trustee hereby agree as follows: 

 1. Usage of Terms. Effective immediately following the effectiveness of the
Conversion, on the date of this Supplemental Indenture, to cure an ambiguity resulting therefrom: 
  

	 	a.	 The definition of the term “Board of Trustees” in Section 101 of the Indenture shall be amended
in its entirety to read as follows: “Board of Trustees” means the board of trustees of Federal Realty Investment Trust, a Maryland real estate investment trust, the executive committee thereof or any committee of that board
duly authorized hereunder. 

  

	 	b.	 As used in (i) the defined terms “Company Request,” “Company Order” and
“Officers’ Certificate” and (ii) Section 303 of the Indenture, the term “trustee” shall be understood to mean a member of the Board of Trustees of Federal Realty Investment Trust, a Maryland real estate investment
trust. 

 2. Capitalized Terms. Capitalized terms used but not defined herein shall have the meanings given to them
in the Indenture. 
 3. Governing Law. This Supplemental Indenture shall be governed by and construed in accordance with the law of
the State of New York. 
 4. Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy
shall be an original, but all of them together represent the same agreement. 
 5. The Trustee. The Trustee shall not be responsible
in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company. 

[Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

			
	FEDERAL REALTY OP LP
		
	By:	 	 /s/ Dawn M. Becker

		 	Name: Dawn M. Becker
		 	Title:   Executive Vice President-Corporate
	
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/ Paul Vaden

		 	Name: Paul Vaden
		 	Title:   Executive Vice President-Corporate

  

  
 First Supplemental
Indenture – 1998 Indenturesprb-ex101_7.htm

Exhibit 10.1

 

 

 

December 29, 2021

Javier B. Szwarcberg, M.D., M.P.H.

jszwarcberg@gmail.com

 

Re: Employment Terms

Dear Javier,

Spruce Biosciences, Inc., a Delaware corporation (the "Company"), is pleased to offer you full-time employment in the regular exempt position of Chief Executive Officer effective as of January 3, 2022 (your “Start Date”). You will report to the Board of Directors of the Company (the "Board"). Your position will be headquartered in our offices located in Daly City, California, or such other location as the Company may designate, except for such travel as may be necessary to fulfill your responsibilities. In the course of your employment with the Company, you will be subject to and required to comply with all company policies, and applicable laws and regulations.

You will be paid a base salary at the annual rate of $540,000 subject to required tax withholding and other authorized deductions. Your base salary will be payable in accordance with the Company's standard payroll policies and subject to adjustment pursuant to the Company's policies as in effect from time to time.

In addition to your base salary, you may be eligible to earn an annual cash performance bonus, at the discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”), based on the attainment of corporate performance metrics and/or individual performance objectives, in each case established and evaluated by the Board or Compensation Committee in its sole good faith discretion. Your target annual bonus shall be 50% of your base salary, but the actual amount of your annual bonus may be more or less, depending on the attainment of applicable performance criteria and Company achievements. Such annual bonus shall be paid within three months following the year to which the annual bonus relates and will be contingent upon your continued employment through the applicable payment date (provided that if your employment is terminated by the Company without Cause (as defined in the Equity Plan (as defined below) or as the result of your death or disability, then in any such case you will receive any earned but unpaid annual bonus relating to the immediately preceding calendar year at the same time as if no such termination had occurred). You hereby acknowledge and agree that nothing contained herein confers upon you any right to an annual bonus in any year, and that whether the Company pays you an annual bonus and the amount of any such annual bonus will be determined by the Board or Compensation Committee in its sole good faith discretion.

In connection with entering into this offer letter, upon or promptly following your Start Date, the Board or the Compensation Committee will grant you an option to purchase 750,000 shares of the Company's common stock (the "First Stock Option") at a per share exercise price equal to the fair market value of one share of the Company's common stock on the date of grant. Subject to your continued 

2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

 

employment with the Company through the applicable vesting date, 25% of the shares underlying the First Stock Option will vest on the first anniversary of your Start Date and 1/48th of the total number of shares underlying the First Stock Option will vest monthly thereafter.

In addition, in connection with entering into this offer letter, upon or promptly following your Start Date, the Board or the Compensation Committee will grant you an additional option to purchase 250,000 shares of the Company's common stock (the "Second Stock Option") at a per share exercise price equal to the fair market value of one share of the Company's common stock on the date of grant. Subject to your continued employment with the Company through the applicable vesting date, 50% of the shares underlying the Second Stock Option will vest on the successful enrollment of the CAHmelia-204 clinical trial, and 50% of the total number of shares underlying the Second Stock Option will vest on the announcement of positive data from the CAHmelia-204 clinical trial, in each case as determined by the Board or the Compensation Committee in its sole good faith discretion.

The First Stock Option and the Second Stock Option are each intended to be a material inducement to your acceptance of this offer of employment, and will be granted as inducement awards outside the Company’s 2020 Equity Incentive Plan (the “Equity Plan”) but pursuant to the terms of the Equity Plan as if the First Stock Option and the Second Stock Option were granted under the Equity Plan and the applicable forms of stock option agreement thereunder.

In addition to the First Stock Option and the Second Stock Option, you may be eligible to receive further annual equity awards pursuant to the Equity Plan, at the discretion of the Board or the Compensation Committee.

You will be entitled to participate in the Company's Severance and Change of Control Plan (the "Severance Plan"), a copy of which will be separately provided to you, provided that the enhanced benefits under the Severance Plan applicable to a Change of Control Termination (as defined in the Severance Plan) will only apply for a Change in Control (as defined in the Severance Plan) with an effective date on or after the first anniversary of your Start Date. 

You will be eligible to participate in all of the employee benefits and benefit plans that the Company generally makes available to its regular full-time employees, including group health plans, life and disability insurances, and a 401(k) plan. In addition, during your employment, you will be eligible for other standard benefits, such as paid time off and holidays to the extent applicable generally to other similarly situated employees of the Company. The Company reserves the right to terminate, modify or add to its benefits and benefit plans at any time.

The Company requires that, as a full-time employee, you devote your full business time, attention, skill, and efforts to the tasks and duties of your position as assigned by the Company. Accordingly, you may not provide services (for any or no form of compensation) for any other person or business entity while employed by the Company, without prior authorization and approval from the Board.

As an executive officer of the Company, you will be entitled to indemnification as provided under the Company's bylaws and other governing documents in effect as of the date hereof to the fullest extent permitted by applicable law. The Company and you intend that such obligation shall remain in full force and 

2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

 

effect, such that a future change in the Company's bylaws other than a change required by applicable law, shall not affect the Company's obligations hereunder. You will be covered by the Company’s directors' and officers' liability insurance policy on the same basis as other executive officers of the Company.

As a condition of employment, you will be required to (1) sign and comply with a Proprietary Information and Inventions Assignment Agreement, a copy of which will be separately provided to you, which, among other things, prohibits unauthorized use or disclosure of Company proprietary information, (2) sign and return a satisfactory I-9 Immigration form and provide sufficient documentation establishing your employment eligibility in the United States of America, and (3) provide satisfactory proof of your identity as required by United States law. This offer, and any employment pursuant to this offer, is also conditioned upon your consent to, and results satisfactory to the Company of reference and background checks. Until you have been informed in writing by Company that such checks have been completed and the results found satisfactory, you may wish to defer reliance on this offer. By signing below, you represent that your performance of services to the Company will not violate any duty which you may have to any other person or entity (such as a present or former employer), including obligations concerning providing services (whether or not competitive) to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or copyrights, and you agree that you will not do anything in the performance of services hereunder that would violate any such duty.

Notwithstanding any of the above, your employment with the Company is "at will". This means that it is not for any specified period of time and can be terminated by you or by the Company at any time, with or without advance notice, and for any or no particular reason or cause. This "at-will" nature of your employment shall remain unchanged during your tenure as an employee and may not be changed, except in an express writing signed by you and another authorized officer of the Company.

If you accept this offer, this letter, the Proprietary Information and Invention Assignment Agreement, and the other plans, policies and agreements referred to herein shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment. Any prior or contemporaneous representations (whether oral or written) not contained herein or therein or contrary to those contained herein or therein, that may have been made to you are expressly cancelled and superseded by this offer. This offer letter shall be interpreted and construed in accordance with California law without regard to any conflicts of laws principles.

Please sign and date this letter and the Proprietary Information and Invention Assignment Agreement, and return it to me by December 31, 2021 if you wish to accept employment at the Company under the terms described above, after which time this offer of employment will expire. If you accept our offer, we would like you to commence your employment with us as soon as practicable.

2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

 

 

We look forward to your favorable reply and to a productive and enjoyable work relationship.

Sincerely,

 

/s/ Michael Grey

Michael Grey

Spruce Biosciences, Inc.

Accepted by:

/s/ Javier B. Szwarcberg, M.D., M.P.H.

[signature]

Javier B. Szwarcberg, M.D., M.P.H.

[name]

December 29, 2021

Date

2001 Junipero Serra Boulevard | Suite 640 | Daly City, CA 94014

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]